
ChromaDex Corp (NAGE) Stock Forecast & Price Target
ChromaDex Corp (NAGE) Analyst Ratings
Bulls say
Niagen Bioscience is poised for long-term success due to its leadership in NAD+ science, innovative NAD+-boosting solutions and strategic initiatives such as the introduction of a pen-like autoinjector, establishing a USP monograph for nicotinamide riboside chloride, expanding its 503B network, and partnering with cruise ships. The company has multiple methods to drive growth, and with the increasing focus on health and wellness, it is likely to continue to outperform its competitors in the longevity and injectable industries, which are projected to grow at impressive rates.
Bears say
Niagen Bioscience is currently facing a lawsuit against regulators over the FDA's decision to allow the sale of NMN products, potentially providing a long-term tailwind. Additionally, their launch of a clinician-directed telehealth platform for their Niagen Plus product and the availability of their Niagen At-Home Injection Kit may expand their addressable market and drive revenue in the coming quarters. Despite a recent pullback in the stock price, the risk/reward remains attractive with Niagen trading at lower earnings and EBITDA multiples compared to other supplement companies, and the potential value of their Ataxia Telangiectasia opportunity could add $5 in share value.
This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.
ChromaDex Corp (NAGE) Analyst Forecast & Price Prediction
Start investing in ChromaDex Corp (NAGE)
Order type
Buy in
Order amount
Est. shares
0 shares